MAPK6-DT

Across TCGA pan-cancer cohorts, MAPK6-DT RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated MAPK6-DT data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MAPK6-DT RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAPK6-DT expression acts as an unfavorable survival marker, although some lineages such as LAML and LUSC show a favorable association.

ACC, UVM, and STAD are the cancer types where MAPK6-DT RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Tertile	All	0.364	0.735	<.001	87	view →
UVM	DFS	Tertile	III,IV	0.355	0.865	<.001	45	view →
STAD	DFS	Quartile	II,III,IV	0.405	0.635	.002	43	view →
COAD	OS	Median	III,IV	0.224	0.759	<.001	41	view →
LAML	DFS	Median	All	0.712	0.418	.002	36	view →
LUSC	OS	Quartile	II,III,IV	0.831	0.564	.001	31	view →
UCEC	OS	Quartile	III,IV	0.850	0.513	.005	30	view →
KIRC	DFS	Median	IV	0.455	0.757	.005	28	view →
UCS	DFS	Median	III,IV	0.591	0.249	.002	26	view →
BRCA	OS	Tertile	III,IV	0.484	0.696	.007	22	view →
KIRP	DFS	Median	All	0.388	0.727	.011	22	view →
DLBC	DFS	Tertile	All	0.477	0.951	.008	21	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

MAPK6-DT–ACC (DFS)

Open the ACC breakdown →